Early Use of High-Efficacy Anti-CD20 Therapy Ofatumumab in Relapsing MS

Williams describes how the shift toward early use of high-efficacy therapy in relapsing MS has brought ofatumumab, an at-home, subcutaneous anti-CD20 agent, into treatment discussions at the start of the disease course.

Williams outlines how active disease features, lifestyle needs, and prior experience with injectable therapies inform selection of ofatumumab as a high-efficacy, self-administered option for patients with relapsing multiple sclerosis.